IQOS Iluma cartridges to feature support messages as Philip Morris highlights vulnerable groups

Oct.28.2024

PMI has announced plans to add support messages for at-risk families to the packaging of TEREA, Marlboro and other brands to raise awareness among economically disadvantaged households. The initiative, part of PMI's collaboration with South Korea's Ministry of the Interior and Safety, will be rolled out across all 50 product lines from January next year.

Philip Morris International (PMI) Korea announced that it will print advertisements for at-risk family support on the packaging of its flagship products, including TEREA and Marlboro cigarettes, according to an N.News report on 28 October. This initiative will be gradually implemented in convenience stores nationwide.

The aim of the campaign is to inform families in financial difficulty that they can contact the Health and Welfare Consultation Centre (129) or their local government office for comprehensive counselling, emergency welfare support and assistance with essential goods. From January next year, the company plans to apply this message to all 50 of its products.

This is one of the outcomes of the 'Identifying and Supporting Families at Risk' agreement that PMI signed with the Ministry of the Interior in July. The slogan will be applied to four products, including the exclusive IQOS Iluma Pod, TEREA Purple Wave, TEREA Blue and Marlboro Gold and Marlboro Red.

The South Korean PMI representative said: "It is very meaningful to be able to use our products to eliminate welfare blind spots and raise society's awareness of families in crisis. As a member of corporate citizenship, we will strive to focus on and contribute to those in need".

References:

[1] 한국필립모리스, 담배 4종에 위기가구 발굴 홍보 문구 적용

Also Read:

[1] Philip Morris Korea launches 'TEREA Black Ruby' to expand IQOS line to 18 varieties

[2] PMI reports strong Q3 performance: Smoke-free product users reach 36.5 million, ZYN sales up 41.4% in the US

[3] PMI Real-Time Audio Webcast of Q3 2024 Financial Results

[4] PMJ Launches New "TEREA Black Sunshine Menthol" Flavor for IQOS

[5] PMJ to Launch Limited Edition IQOS Iluma i Anniversary Model!

[6] Illegal Tobacco Trade in UK: Rising Concerns and Solutions

[7] PMI Korea Launches New Pod for IQOS ILUMA

[8] PMI Aims to Bring ZYN Nicotine Pouches to Germany and Accelerates Pod-Based E-Cigarette Rollout

[9] PMI Sells Vectura Group Ltd. to Molex Asia Holdings

[10] New "TEREA" Pod Flavors Launched by Philip Morris Japan

[11] PMI Discount Offer: VEEV One & Zyn Bundle at Vape UK

[12] PMI Korea Introduces New Marlboro Vista Series 'Garden Splash'

#PMI

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance

FDA’s launch of a web-based PMTA system signals faster reviews and, 2Firsts experts say, a possible inflection point for the U.S. e-cigarette market’s shift out of the grey zone.

Dec.04

British American Tobacco’s VELO Launches Limited McLaren F1 Edition: US Price Only 60% of EU/UK

BAT’s VELO has released a McLaren F1 co-branded, track-themed limited-edition pack in McLaren’s orange-black livery. Pricing is about $4.60 per can in the U.S. versus ~$7.40 in the EU/UK. The collaboration extends BAT’s partnership with McLaren dating back to 2019.

Oct.11 by 2FIRSTS.ai

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement

President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.

Nov.14 by 2FIRSTS.ai

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.